BNP Paribas Financial Markets
ERNA icon

BNP Paribas Financial Markets’s Eterna Therapeutics ERNA Stock Holding History

BNP Paribas Financial Markets’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7 Buy
+1
New +$7 ﹤0.01% 5877
2026
Q1 		– Hold
0
– – – 5792
2025
Q4 		– Hold
0
– – – 5688
2025
Q3 		– Hold
0
– – – 5517
2025
Q2 		– Hold
0
– – – 5395
2025
Q1 		– Hold
0
– – – 5315
2024
Q4 		– Hold
0
– – – 5324

Other funds holding ERNA

VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tradewinds Capital Management Bellingham, Washington $563M AUM 41.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

BNP Paribas Financial Markets's ERNA Position: Q2 2026 in Review

BNP Paribas Financial Markets opened a new position in Eterna Therapeutics (ERNA) in Q2 2026: 1 share worth $7. The stake represents ﹤0.01% of the portfolio and ranks #5877 among its holdings.

8 funds tracked by Wall St. Rank hold ERNA as of Q2 2026.

  • BNP Paribas Financial Markets held 1 share of Eterna Therapeutics worth $7 as of Q2 2026.
  • Eterna Therapeutics was a new BNP Paribas Financial Markets position in Q2 2026.
  • Eterna Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5877 holding.
  • 8 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.